CClinicalTrials.gg
RecruitingNCT05933694SPIRO-AIDUpdated Feb 16, 2024

Spirometry Interpretation Performance of Primary Care Clinicians With/Without AI Software

An interventional study of Artificial Intelligence-powered Spirometry Interpretation Report in Lung Disease, sponsored by Royal Brompton & Harefield NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by Royal Brompton & Harefield NHS Foundation Trust · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

To evaluate whether an artificial intelligence decision support software (ArtiQ.Spiro) improves the diagnostic accuracy of spirometry interpreted by primary care clinicians, as measured by Clinician Diagnostic Accuracy (vs Reference Standard).

Read the detailed description

This is a randomised controlled study to evaluate the effects of AI support software on the performance of primary care clinicians in the interpretation of spirometry. Clinicians will be provided with a clinical dataset of 50 entirely anonymous, previously recorded real-world spirometry records to interpret and will be asked to complete specific questions about diagnosis and quality assessment. The records will be randomly selected from a database comprising spirometry records from 1122 patients undergoing spirometry in primary care and community -based respiratory clinics in Hillingdon borough between 2015-2018.

Participating clinicians will be allocated at random to receive either spirometry records alone or spirometry records with the addition of an AI spirometry interpretation eport. The clinical spirometry records will be de-identified (name, date of birth, address, postcode, occupation, GP, medications data removed), by a member of the clinical care team.

Study participants (participating clinicians) will independently examine the same 50 spirometry records through an online platform. For each spirometry record, the primary care clinician participant will answer questions about technical quality, pattern interpretation, preferred diagnosis, differential diagnosis and self-rated confidence with these answers.

The study statistician will be blinded to treatment allocation up to completion of analysis and interpretation.

The reference standards for spirometry technical quality and pattern interpretation will be made by a senior experienced respiratory physiologist but without access to AI report.

The reference standard for diagnosis will be made by a panel of three respiratory specialists from the clinical care team with access to medical notes and results of relevant investigations but without access to AI report.

02

Conditions studied

  • Lung Disease

Browse trials for

03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's planned enrollment of 228 is above the median of 72 across 2,118 interventional studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

Royal Brompton & Harefield NHS Foundation Trust is the lead sponsor of 137 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Clinicians working in primary care (for at least 50% of their job plan) in the UK, who refer for or perform spirometry (typically GP, practice nurse)
  2. Able to access spirometry traces on study platform
  3. Provide written informed consent via study platform

Exclusion criteria

Exclusion Criteria:

  1. Clinicians who have completed specialist training in respiratory medicine and recognised by the General Medical Council with a right to practise as a NHS consultant in respiratory medicine
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
228 participants (estimated)

Study arms

  • No intervention
    Control

    Participants to report 50 spirometry records alone

  • Experimental
    Intervention

    Participants report the same 50 spirometry records provided in the control arm with an artificial intelligence-powered spirometry interpretation report

    Other: Artificial Intelligence-powered Spirometry Interpretation Report

Interventions

  • OtherArtificial Intelligence-powered Spirometry Interpretation Report

    A report generated by artificial intelligence powered software that assessed technical quality of spirometry and estimates the diagnostic probability of six categories: COPD/Asthma/ILD/ Normal/Other obstructive/Other Unidentified

    Also known as: ArtiQ.Spiro

06

What researchers measure

Primary outcomes

  1. Preferred Diagnostic Performance

    A correct case is where the preferred diagnosis matches the reference final diagnosis. Units will be percentage of total cases that are correct.

    Time frame: Six months

Secondary outcomes

  1. Pattern interpretation

    A correct case is where the participants' selected pattern matches the reference pattern. Options are: Normal, Airflow obstruction, Possible restriction or non-specific pattern, Possible Mixed Disorder. Units will be percentage of total cases that are correct.

    Time frame: Six months

  2. Differential diagnostic performance

    A correct case is where the preferred or differential diagnosis matches the reference final diagnosis. Units will be percentage of total cases that are correct.

    Time frame: Six months

  3. Quality assessment performance

    A correct case is where the participant's quality grade matches the reference quality grade. Options are: Acceptable (Grade A/B) or Not Acceptable (Grades C/D/E/F/U). Units will be percentage of total cases that are correct.

    Time frame: Six months

  4. Pattern interpretation self-rated confidence

    Pattern interpretation self-rated confidence will be measured on a visual analogue scale (0-10) where 0 = not confident at all; 10= very confident)

    Time frame: Six months

  5. Diagnostic self-rated confidence

    Diagnostic self-rated confidence will be measured on a visual analogue scale (0-10) where 0 = not confident at all; 10= very confident)

    Time frame: Six months

  6. Quality Assessment self-rated confidence

    Quality Assessment self-rated confidence will be measured on a visual analogue scale (0-10) where is 0 = not confident at all; 10= very confident)

    Time frame: Six months

07

Study locations

1 of 1 sites recruiting
  • Royal Brompton & Harefield Hospitals
    Uxbridge, UB9 6JH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05933694
Lead sponsor
Royal Brompton & Harefield NHS Foundation Trust
Collaborators
National Institute for Health Research, United Kingdom
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Jun 27, 2023
Primary completion
Jun 27, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Feb 16, 2024

Study contacts

Ethaar El-Emir, PhD
Contact
e.el-emir@rbht.nhs.uk
01895 823737 ext. 85952
George Edwards, MSc
Contact
G.Edwards2@rbht.nhs.uk
01895 823737
William Man
principal investigator · Royal Brompton & Harefield Hospitals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion